Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Opportunities: Insights from 2025–2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Expected To Expand Between 2025 And 2029?
The chronic inflammatory demyelinating polyneuropathy (cidp) market size has demonstrated robust growth over recent years. It is anticipated to increase from $2.1 billion in 2024 to $2.27 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.1%. This historical expansion can be linked to an expanding geriatric population, advancements in treatment options, heightened awareness leading to early diagnosis, progress in immunology and autoimmune research, and the growing incidence of autoimmune diseases.
The chronic inflammatory demyelinating polyneuropathy (cidp) market is anticipated to experience robust growth in the coming years. It is projected to expand to $3.09 billion by 2029, driven by a compound annual growth rate (CAGR) of 7.9%. This expansion during the forecast period is attributable to factors such as an aging global populace, a heightened focus on rare and autoimmune diseases, better access to healthcare services, active patient advocacy and awareness initiatives, and advancements in healthcare infrastructure. Significant trends expected during this timeframe include an increasing prevalence of chronic inflammatory demyelinating polyneuropathy, continuous improvements in treatment options, escalating research and development activities, the emergence of biosimilar therapies, and the progression of personalized medicine approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
The expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to be propelled by increasing healthcare expenditure in the future. This rise in healthcare spending is a result of higher investments in medical infrastructure, an increasing demand for advanced treatments, broader insurance coverage, and government efforts aimed at enhancing healthcare accessibility. Significant healthcare expenditure facilitates better access to advanced treatments, prompt diagnosis, and improved management of CIDP, thereby enhancing patient outcomes and quality of life. For example, in May 2024, the Office for National Statistics, a UK-based government department, stated that total healthcare expenditure witnessed a 5.6% nominal increase from 2022 to 2023, marking a considerable acceleration when compared to the 0.9% growth observed in 2022. Consequently, the increasing healthcare expenditure is a significant factor driving the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
What Are The Major Segment Categories Driving The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth?
The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
What Are The Latest Industry Trends Transforming The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Leading firms within the chronic inflammatory demyelinating polyneuropathy (CIDP) market are prioritizing innovations, particularly intravenous immunoglobulin (IVIG) therapy, with the goal of boosting treatment effectiveness, enhancing patient results, and offering more precise and effective immune system regulation for CIDP management. This therapy involves the infusion of concentrated antibodies sourced from healthy donors, aiming to modulate the immune system and diminish inflammation associated with autoimmune conditions. A notable instance occurred in January 2024, when Takeda Pharmaceutical Company Limited, a biopharmaceutical firm based in Japan, disclosed that GAMMAGARD LIQUID received FDA approval as an intravenous immunoglobulin (IVIG) therapy specifically for adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). This authorization permits its application as an induction therapy, commencing with an initial dosage and subsequently continuing with maintenance doses to facilitate sustained disease management and foster improved neuromuscular capabilities.
Which Leading Players Are Enhancing Their Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Presence Worldwide?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2025, By The Business Research Company
Chronic Disease Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report
Chronic Lower Back Pain Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report
Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
